Key result
AJW200 provided sustained inhibition of platelet aggregation for up to 2 weeks without extensive prolongation of bleeding time compared to abciximab in cynomolgus monkeys.
Why the study?
Does AJW200 inhibit platelet aggregation without extensive bleeding time prolongation in cynomolgus monkeys and human platelets?
Population
Cynomolgus monkeys (in vivo) and human platelets (in vitro)
Comparison
AJW200 single bolus injection at 0.3, 1, and 3… vs Abciximab (0.4 mg/kg) and/or baseline/control
Design
Preclinical
Follow-up
Up to 2 weeks
Authors
Loading...
Does not support clinical use; leaves open translation of sustained GPIb-vWF inhibition to human trials.
Does AJW200 inhibit platelet aggregation without extensive bleeding time prolongation in cynomolgus monkeys and human platelets?
AJW200 provides sustained antiplatelet effects via glycoprotein Ib-vWF blockade without extensive bleeding time prolongation, likely due to its shear-stress-dependent inhibitory action.
Kageyama et al. (2002) studied this question. AJW200 vs. Abciximab was evaluated on Platelet aggregation and bleeding time. AJW200 provided sustained inhibition of platelet aggregation for up to 2 weeks without extensive prolongation of bleeding time compared to abciximab in cynomolgus monkeys.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: